Investigating key epigenetic factors in breast cancer patients
Official title: "Investigating The Role of Key Non-coding RNA(s) in Breast Cancer Patients and Their Possible Crosstalk With Chromatin Remodeling Machinery"
Run by Ain Shams University · NCT06759714 · Data updated 2026-11-12
This study is trying to see if certain genetic markers in newly diagnosed breast cancer patients can help improve how doctors diagnose and treat the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 100 (estimated) |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo) |
| Status | Recruiting |
| Started | November 23, 2024 |
| Main results expected | May 2025 |
| Study ends | December 2025 |
| Registry record updated | January 6, 2025 |
| Trial ID | NCT06759714 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are Egyptian females aged 18 years and above who have been newly diagnosed with breast cancer.
✕Probably not a fit
Patients with blood diseases, other cancers, liver cirrhosis, or evidence of distant metastases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on understanding the role of epigenetic regulators, specifically non-coding RNAs, in breast cancer. It aims to measure the expression levels of UPK1A-AS1 and UNC5B-AS1 in clinical samples from newly diagnosed breast cancer patients. By analyzing these molecular markers, the study seeks to enhance the diagnosis and prognosis of breast cancer, potentially leading to new therapeutic targets. The research highlights the significance of epigenetic dysregulation in cancer and its implications for patient outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and prognostic tools for breast cancer patients.
How similar studies have gone: While this study explores a novel approach, previous research has indicated the potential of epigenetic markers in cancer diagnosis and prognosis.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Egyptian females breast cancer patients aged 18 years and above, newly diagnosed with breast cancer. Exclusion Criteria: Blood diseases, any cancer other than breast cancer, liver cirrhosis and uterine and urinary bladder diseases or breast cancer patients with any evidence of distant metastases.
Where it's running
-
Faculty of pharmacy, Ain Shams University
Cairo, Egypt Recruiting
Study contacts
- Principal investigator: Sherihan Galal, phD — Ain Shams University
- Study coordinator: Sherihan Galal, phD
- Email: Dr.sherehan@pharma.asu.edu.eg
- Phone: 01022850699
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.